ImmPACT Bio USA Inc., a Camarillo, Calif.-based company founded in the FutuRx incubator located in Ness Ziona, Israel, developing novel cell therapies for treating cancer, closed a US$ 18m Series A equity financing round.
EyeControl, a Tel Aviv, Israel-based supplier of assistive communication devices for ventilated and “locked-in” patients, raised $10m.
MobileODT, a Tel Aviv, Israel-based developer of the EVA System for cervical cancer screening, closed a $4m Series C funding round.
Adaptive Shield, a Tel Aviv, Israel-based SaaS application security startup, emerged from stealth with $4m in seed funding.
Perimeter 81, a Tel Aviv, Israel-based Secure Access Service Edge (SASE) and Network as a Service provider, completed a $40m Series B funding round.
Ironscales, a Ramat Gan, Israel-based self-learning email security solutions, closed an $8m Series B extension funding round.
Zencity, a Tel Aviv, Israel-based provider of AI-based insights for local governments, closed a $13.5m funding round.
Joy Ventures, a Tel Aviv, Israel-based startup studio seeding and funding companies building consumer products for emotional wellbeing, launched its Entrepreneur-in-Residence (EIR) platform to establish new startups in the category.
Approve.com, a Tel Aviv, Israel-based modern procurement platform, completed a $5m seed funding round.
Sight Diagnostics, a Tel Aviv, Israel-based maker of an FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, raised $71m in Series D funding.
Voiceitt, a Ramat Gan, Israel-based commercial speech recognition technology platform, raised an additional $10m in a Series-A funding round.
Silverfort, a Boston, MA and Tel Aviv, Israel-baserd provider of an agentless, proxyless authentication platform, raised $30m in series B funding round.
Ecoplant, a Kibbutz Gevim, Israel-based provider of industrial IoT solutions, raised €8m as part of a Series A funding round.
Trobix Innovation Ltd., a Netanya, Israel-based biotechnology company developing therapies to remove the threat of antimicrobial resistance, closed a US $ 3M Series A funding.
Caps Medical, a Netanya, Israel-based developer of a highly selective and minimally invasive non-thermal plasma device for cancer treatment, completed a $3.5m Series A financing round.